This is a multicenter, prospective, non-interventional, observational single arm study.
100 patients will be recruited in the Netherlands over a one year period. In all cases, the
decision to treat the patient with apremilast will be made prior to the decision to enter the
subject into this study. Treatment will be according to routine clinical practice and based
on recommendations as per the Summary of Product Characteristics (SPC) of apremilast
(Otezla®). Each patient will be followed up for a maximum of 24 months.